OxOnc Development Services, Pfizer deal

Pfizer partnered with oncology development company OxOnc to conduct an Asian pivotal trial to evaluate Pfizer's Xalkori crizotinib to treat patients with advanced non-small cell lung cancer (NSCLC) with c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements. OxOnc will provide funding and supervision for the trial, which will be conducted in Japan, China, Taiwan and South Korea and assess the safety and efficacy of Xalkori. If Xalkori is approved for the indication, OxOnc will be eligible for milestones. OxOnc declined to disclose details, while Pfizer could not be reached. ...